Ascletis Pharma Inc (2VJ) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.013x

Based on the latest financial reports, Ascletis Pharma Inc (2VJ) has a cash flow conversion efficiency ratio of -0.013x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-33.98 Million ≈ $-39.73 Million USD) by net assets (€2.57 Billion ≈ $3.00 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ascletis Pharma Inc - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Ascletis Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 2VJ liabilities breakdown for a breakdown of total debt and financial obligations.

Ascletis Pharma Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ascletis Pharma Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hunan Boyun New Materials Co Ltd SHE:002297	0.037x
OCADO GROUP SP.ADR 1/2 F:0OC1	N/A
DCM Shriram Limited NSE:DCMSHRIRAM	0.210x
Bausch Health Companies Inc TO:BHC	1.139x
Rendong Holdings Co Ltd SHE:002647	0.089x
HENSOLDT AG UNSP. ADS F:HAG0	N/A
Electra Ltd TA:ELTR	0.046x
Suzhou TZTEK Technology Co Ltd SHG:688003	0.001x

Annual Cash Flow Conversion Efficiency for Ascletis Pharma Inc (2016–2024)

The table below shows the annual cash flow conversion efficiency of Ascletis Pharma Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Ascletis Pharma Inc.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€1.97 Billion ≈ $2.30 Billion	€-341.58 Million ≈ $-399.34 Million	-0.174x	-81.81%
2023-12-31	€2.34 Billion ≈ $2.74 Billion	€-223.79 Million ≈ $-261.64 Million	-0.096x	-70.37%
2022-12-31	€2.54 Billion ≈ $2.97 Billion	€-142.45 Million ≈ $-166.54 Million	-0.056x	-4.17%
2021-12-31	€2.73 Billion ≈ $3.19 Billion	€-146.93 Million ≈ $-171.78 Million	-0.054x	-89.06%
2020-12-31	€2.98 Billion ≈ $3.49 Billion	€-84.91 Million ≈ $-99.27 Million	-0.028x	-27.34%
2019-12-31	€3.32 Billion ≈ $3.89 Billion	€-74.34 Million ≈ $-86.91 Million	-0.022x	+20.65%
2018-12-31	€3.43 Billion ≈ $4.01 Billion	€-96.59 Million ≈ $-112.92 Million	-0.028x	+87.62%
2017-12-31	€869.83 Million ≈ $1.02 Billion	€-198.06 Million ≈ $-231.55 Million	-0.228x	-645.29%
2016-12-31	€409.08 Million ≈ $478.26 Million	€-12.50 Million ≈ $-14.61 Million	-0.031x	--

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$2.16 Billion

€1.85 Billion EUR

Market Cap Rank

#6152 Global

#923 in Germany

Share Price

€1.75

Change (1 day)

-2.23%

52-Week Range

€0.62 - €1.99

All Time High

€1.99